# Comprehensive Biomarker Profiling of the IFN-α Pathway in Amyotrophic Lateral Sclerosis Patient Biofluids

> **NCT07260981** · — · COMPLETED · sponsor: **Ulysses Neuroscience LTD** · enrollment: 60 (actual)

## Conditions studied

- ALS - Amyotrophic Lateral Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07260981
- **Lead sponsor:** Ulysses Neuroscience LTD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-01
- **Primary completion:** 2025-01-18
- **Final completion:** 2025-01-18
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07260981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07260981, "Comprehensive Biomarker Profiling of the IFN-α Pathway in Amyotrophic Lateral Sclerosis Patient Biofluids". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07260981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*